Compare versions
Version 1 → Version 2 (current). Removed · Added. This shows the entry's text as it is written, including its formatting marks.
Version 1 · Version 2 (current) · Version history
Side by side · Together
Version 1Version 2 (current)
5 unchanged paragraphs
A randomized controlled trial (RCT) is an experiment in which participants are assigned by chance to groups, one receiving the treatment being tested and another, the control group, not, so that differences in outcome can be credited to the treatment.
A randomized controlled trial (RCT) is an experiment in which participants are assigned by chance to groups, one receiving the treatment being tested and another, the control group, not, so that differences in outcome can be credited to the treatment.


*Via Wikimedia Commons: [J. Lind; A treatise of the scurvy. Wellcome L0019183](https://commons.wikimedia.org/wiki/File:J._Lind;_A_treatise_of_the_scurvy._Wellcome_L0019183.jpg), [CC BY 4.0](https://creativecommons.org/licenses/by/4.0).*
*Via Wikimedia Commons: [J. Lind; A treatise of the scurvy. Wellcome L0019183](https://commons.wikimedia.org/wiki/File:J._Lind;_A_treatise_of_the_scurvy._Wellcome_L0019183.jpg), [CC BY 4.0](https://creativecommons.org/licenses/by/4.0).*
## What it is
## What it is
A trial is *controlled* when the people receiving a new treatment are compared with a group who receive something else: no treatment, a placebo (a dummy treatment made to look like the real one), the usual care, or another active treatment. It is *randomized* when chance, not the judgment of the researchers or the participants, decides who goes into which group.
A trial is *controlled* when the people receiving a new treatment are compared with a group who receive something else: no treatment, a placebo (a dummy treatment made to look like the real one), the usual care, or another active treatment. It is *randomized* when chance, not the judgment of the researchers or the participants, decides who goes into which group.
Chance allocation answers a particular problem. If doctors choose which patients get a new treatment, they may, knowingly or not, give it to patients who are healthier or more likely to recover, and the treatment will look better than it is. The statistician Austin Bradford Hill, who designed the random allocation of the landmark 1948 streptomycin trial, valued randomization chiefly for this reason: according to a 2025 history by Robert Matthews for the James Lind Library, Hill [remained convinced that its value in clinical trials lay in its ability to prevent allocation bias](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/), the bias that arises when the person allocating patients influences who goes where. The statistician Ronald Fisher, who developed the theory of randomization for agricultural experiments, justified it on statistical grounds: random allocation gives [a statistically valid estimate of both the treatment effect and the uncertainty around it](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/).
Chance allocation answers a particular problem. If doctors choose which patients get a new treatment, they may, knowingly or not, give it to patients who are healthier or more likely to recover, and the treatment will look better than it is. The statistician Austin Bradford Hill, who designed the random allocation of the landmark 1948 streptomycin trial, valued randomization chiefly for this reason: according to a 2025 history by Robert Matthews for the James Lind Library, Hill [remained convinced that its value in clinical trials lay in its ability to prevent allocation bias](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/), the bias that arises when the person allocating patients influences who goes where.[1] The statistician Ronald Fisher, who developed the theory of randomization for agricultural experiments, justified it on statistical grounds: random allocation gives [a statistically valid estimate of both the treatment effect and the uncertainty around it](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/).[1]
Randomization does not make the groups identical in any single trial. Angus Deaton and Nancy Cartwright point out that it does [not equalize everything other than the treatment](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115): it balances the groups only *in expectation*, that is, on average over the many ways the allocation could have fallen, and a particular trial can still end up with groups that differ by chance. What randomization does guarantee is that such differences are due to chance alone, which is what statistical methods are built to measure.
Randomization does not make the groups identical in any single trial. Angus Deaton and Nancy Cartwright point out that it does [not equalize everything other than the treatment](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115): it balances the groups only *in expectation*, that is, on average over the many ways the allocation could have fallen, and a particular trial can still end up with groups that differ by chance.[8] What randomization does guarantee is that such differences are due to chance alone, which is what statistical methods are built to measure.
Randomized trials are used to test medicines, vaccines, surgical procedures, diets, health services, teaching methods and social and economic policies. In medicine they are generally regarded as strong evidence for judging whether an intervention works, but only when, in the words of the 2025 CONSORT reporting guideline, they are [appropriately designed, conducted, analysed and reported](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996237/).
Randomized trials are used to test medicines, vaccines, surgical procedures, diets, health services, teaching methods and social and economic policies. In medicine they are generally regarded as strong evidence for judging whether an intervention works, but only when, in the words of the 2025 CONSORT reporting guideline, they are [appropriately designed, conducted, analysed and reported](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996237/).[9]
## History
## History
### Early controlled comparisons
### Early controlled comparisons
Comparing treatments side by side is much older than randomization. The best-known early example is James Lind's experiment on scurvy. In his *Treatise of the Scurvy*, first published in Edinburgh in [1753](https://www.jameslindlibrary.org/lind-j-1753/), Lind described how on [20 May 1747 he selected twelve patients with scurvy on board the *Salisbury* at sea](https://archive.org/details/b30511902), whose cases were "as similar as I could have them," kept them in one place on one common diet, and gave pairs of them six different remedies: cider, elixir of vitriol, vinegar, sea water, two oranges and a lemon a day, and a medicinal paste of garlic, mustard seed and other ingredients. In the text of the third edition (1772) he reported that "the most sudden and visible good effects were perceived from the use of oranges and lemons," one of the two men given them being fit for duty after six days.
Comparing treatments side by side is much older than randomization. The best-known early example is James Lind's experiment on scurvy. In his *Treatise of the Scurvy*, first published in Edinburgh in [1753](https://www.jameslindlibrary.org/lind-j-1753/), Lind described how on [20 May 1747 he selected twelve patients with scurvy on board the *Salisbury* at sea](https://archive.org/details/b30511902), whose cases were "as similar as I could have them," kept them in one place on one common diet, and gave pairs of them six different remedies: cider, elixir of vitriol, vinegar, sea water, two oranges and a lemon a day, and a medicinal paste of garlic, mustard seed and other ingredients.[2][3] In the text of the third edition (1772) he reported that "the most sudden and visible good effects were perceived from the use of oranges and lemons," one of the two men given them being fit for duty after six days.[2]
Lind's trial was controlled but not randomized. He chose who got which remedy himself, and his own account says that [two of the worst patients were put on sea water](https://archive.org/details/b30511902), exactly the kind of choice that random allocation was later designed to prevent.
Lind's trial was controlled but not randomized. He chose who got which remedy himself, and his own account says that [two of the worst patients were put on sea water](https://archive.org/details/b30511902), exactly the kind of choice that random allocation was later designed to prevent.[2]
Over the following century, trials more often divided patients by *alternation*, giving each successive patient the other treatment. Matthews traces the prominence of alternation to the mid-1800s and notes that it remained [the main approach until the early 1960s](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/); Fibiger's 1898 trial of diphtheria serum used it, although its author described his patients as "randomly selected." Alternation looks fair, but anyone who knows the sequence can predict the next assignment. The same history identifies the 1835 Nuremberg salt test as [the oldest known report of randomised allocation in a clinical trial](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/), and notes sporadic earlier use of random allocation.
Over the following century, trials more often divided patients by *alternation*, giving each successive patient the other treatment. Matthews traces the prominence of alternation to the mid-1800s and notes that it remained [the main approach until the early 1960s](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/); Fibiger's 1898 trial of diphtheria serum used it, although its author described his patients as "randomly selected." Alternation looks fair, but anyone who knows the sequence can predict the next assignment.[6] The same history identifies the 1835 Nuremberg salt test as [the oldest known report of randomised allocation in a clinical trial](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/), and notes sporadic earlier use of random allocation.[1]
### Fisher and agricultural experiments
### Fisher and agricultural experiments
The theory came from agriculture. Fisher developed it while working at the Rothamsted agricultural research institute in the 1920s, and his books *Statistical Methods for Research Workers* (1925) and *The Design of Experiments* (1935) [carried his influence from crop trials into clinical research](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/). Fisher wrote in 1935 that randomization "relieves the experimenter from the anxiety of considering and estimating the magnitude of the innumerable causes" that might otherwise disturb the result.
The theory came from agriculture. Fisher developed it while working at the Rothamsted agricultural research institute in the 1920s, and his books *Statistical Methods for Research Workers* (1925) and *The Design of Experiments* (1935) [carried his influence from crop trials into clinical research](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/).[1] Fisher wrote in 1935 that randomization "relieves the experimenter from the anxiety of considering and estimating the magnitude of the innumerable causes" that might otherwise disturb the result.[1]
### The 1948 streptomycin trial
### The 1948 streptomycin trial
The trial usually taken as the start of the modern clinical trial was the British Medical Research Council's (MRC) test of the antibiotic streptomycin for pulmonary tuberculosis, published in the *British Medical Journal* on 30 October 1948. Matthews describes it as [generally regarded as marking the emergence of the modern clinical trial](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/), with a random allocation method designed by Bradford Hill.
The trial usually taken as the start of the modern clinical trial was the British Medical Research Council's (MRC) test of the antibiotic streptomycin for pulmonary tuberculosis, published in the *British Medical Journal* on 30 October 1948. Matthews describes it as [generally regarded as marking the emergence of the modern clinical trial](https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/), with a random allocation method designed by Bradford Hill.[1]
John Crofton, writing in 2006, recalled that a control group was accepted partly because of a shortage: Britain's lack of dollars meant [the government was only prepared to purchase a limited quantity of the drug](https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/), and given the uncertain course of the disease and the limited supply, Hill argued that a comparison group was justified. Each sex in each hospital was given a numbered series of sealed envelopes, whose order was based on a series of random numbers, so that no clinician could know in advance which treatment the next patient would receive. Chest X-rays were assessed by three specialists who did not know which group each patient was in.
John Crofton, writing in 2006, recalled that a control group was accepted partly because of a shortage: Britain's lack of dollars meant [the government was only prepared to purchase a limited quantity of the drug](https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/), and given the uncertain course of the disease and the limited supply, Hill argued that a comparison group was justified.[4] Each sex in each hospital was given a numbered series of sealed envelopes, whose order was based on a series of random numbers, so that no clinician could know in advance which treatment the next patient would receive. Chest X-rays were assessed by three specialists who did not know which group each patient was in.[4]
After six months, [4 of the 55 patients allocated streptomycin had died, compared with 15 of the 52 allocated bed rest alone](https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/). The trial also exposed a weakness of the drug: tubercle bacilli could still be cultured from 47 of the 55 treated patients, and deterioration among them coincided with the bacteria becoming resistant to streptomycin. Crofton describes the study as [widely regarded as a milestone in the history of clinical trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/).
After six months, [4 of the 55 patients allocated streptomycin had died, compared with 15 of the 52 allocated bed rest alone](https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/).[4] The trial also exposed a weakness of the drug: tubercle bacilli could still be cultured from 47 of the 55 treated patients, and deterioration among them coincided with the bacteria becoming resistant to streptomycin.[4] Crofton describes the study as [widely regarded as a milestone in the history of clinical trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/).[4]
## How a trial is designed
## How a trial is designed
### Random allocation and concealment
### Random allocation and concealment
Generating a random sequence is not enough; the people enrolling participants must not know what comes next. The Cochrane Handbook, the methods manual for the Cochrane systematic reviews, calls [successful allocation sequence concealment a vital part of randomization](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08), because knowing the next assignment can allow selective enrolment of participants on the basis of how well they are likely to do. It lists the ways concealment fails, including a predictable rule such as alternation, date of birth or day of admission, and envelopes that are unsealed or translucent enough to be held against a light.
Generating a random sequence is not enough; the people enrolling participants must not know what comes next. The Cochrane Handbook, the methods manual for the Cochrane systematic reviews, calls [successful allocation sequence concealment a vital part of randomization](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08), because knowing the next assignment can allow selective enrolment of participants on the basis of how well they are likely to do.[6] It lists the ways concealment fails, including a predictable rule such as alternation, date of birth or day of admission, and envelopes that are unsealed or translucent enough to be held against a light.[6]
### Blinding and placebos
### Blinding and placebos
A trial is *blinded* (or *masked*) when participants, the people treating them, or those measuring outcomes do not know who received which intervention; "double-blind" usually means that neither participants nor investigators know. Blinding stops expectations from changing how people behave, how they are treated, or how outcomes are judged. A placebo makes this possible when the treatment is a pill or injection. The Cochrane Handbook cautions that an attempt to blind [does not ensure successful blinding in practice](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08), since side effects or other clues can reveal the assignment.
A trial is *blinded* (or *masked*) when participants, the people treating them, or those measuring outcomes do not know who received which intervention; "double-blind" usually means that neither participants nor investigators know. Blinding stops expectations from changing how people behave, how they are treated, or how outcomes are judged. A placebo makes this possible when the treatment is a pill or injection. The Cochrane Handbook cautions that an attempt to blind [does not ensure successful blinding in practice](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08), since side effects or other clues can reveal the assignment.[6]
Many trials cannot be blinded at all, such as those comparing surgery with medication, or most trials of social policy. Deaton and Cartwright note that [many social and economic trials, medical trials and public health trials are not blinded, and many cannot be](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115). A trial in which everyone knows the assignments is called *open-label*.
Many trials cannot be blinded at all, such as those comparing surgery with medication, or most trials of social policy. Deaton and Cartwright note that [many social and economic trials, medical trials and public health trials are not blinded, and many cannot be](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115).[8] A trial in which everyone knows the assignments is called *open-label*.
### Analysis
### Analysis
Once allocated, participants are normally analysed in the group they were assigned to, whether or not they took the treatment as planned. This is the *intention-to-treat* principle, which the Cochrane Handbook describes as analysing participants [in the intervention groups to which they were randomized and including all randomized participants in the analysis](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08). Dropping people who stopped treatment, for example, could reintroduce the very differences between groups that randomization removed.
Once allocated, participants are normally analysed in the group they were assigned to, whether or not they took the treatment as planned. This is the *intention-to-treat* principle, which the Cochrane Handbook describes as analysing participants [in the intervention groups to which they were randomized and including all randomized participants in the analysis](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08).[6] Dropping people who stopped treatment, for example, could reintroduce the very differences between groups that randomization removed.
The Handbook's tool for judging a trial's risk of bias, known as RoB 2, looks at five areas: [bias arising from the randomization process, from deviations from intended interventions, from missing outcome data, in measurement of the outcome, and in selection of the reported result](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08).
The Handbook's tool for judging a trial's risk of bias, known as RoB 2, looks at five areas: [bias arising from the randomization process, from deviations from intended interventions, from missing outcome data, in measurement of the outcome, and in selection of the reported result](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08).[6]
### Variants
### Variants
In the commonest design, the *parallel-group* trial, each participant receives one intervention. Other designs randomize differently:
In the commonest design, the *parallel-group* trial, each participant receives one intervention. Other designs randomize differently:
- In a **cluster-randomized trial**, [groups of individuals rather than individuals are randomized](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23), such as schools, villages, medical practices or families. It suits interventions that act on a whole group, such as herd immunity from vaccination, or that would spill over between people in the same place. Analysing such a trial as if individuals had been randomized makes its confidence intervals artificially narrow.
- In a **crossover trial**, [every participant receives every intervention](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23) in a randomly ordered sequence, often with a "wash-out" period between them so that the effect of the first does not carry over into the second.
- **Very large trials** can answer urgent questions quickly. The RECOVERY trial, an open-label trial in patients hospitalized with COVID-19 at [176 National Health Service organizations in the United Kingdom](https://pmc.ncbi.nlm.nih.gov/articles/PMC7383595/), randomly assigned [2,104 patients to the steroid dexamethasone and 4,321 to usual care](https://pmc.ncbi.nlm.nih.gov/articles/PMC7383595/); within 28 days 22.9 percent of the dexamethasone group and 25.7 percent of the usual-care group had died. The benefit was found among patients receiving oxygen or mechanical ventilation, but not among those receiving no respiratory support.
### Phases of drug trials
- In a **cluster-randomized trial**, [groups of individuals rather than individuals are randomized](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23), such as schools, villages, medical practices or families.[7] It suits interventions that act on a whole group, such as herd immunity from vaccination, or that would spill over between people in the same place. Analysing such a trial as if individuals had been randomized makes its confidence intervals artificially narrow.[7]
- In a **crossover trial**, [every participant receives every intervention](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23) in a randomly ordered sequence, often with a "wash-out" period between them so that the effect of the first does not carry over into the second.[7]
- **Very large trials** can answer urgent questions quickly. The RECOVERY trial, an open-label trial in patients hospitalized with COVID-19 at [176 National Health Service organizations in the United Kingdom](https://pmc.ncbi.nlm.nih.gov/articles/PMC7383595/), randomly assigned [2,104 patients to the steroid dexamethasone and 4,321 to usual care](https://pmc.ncbi.nlm.nih.gov/articles/PMC7383595/); within 28 days 22.9 percent of the dexamethasone group and 25.7 percent of the usual-care group had died.[12] The benefit was found among patients receiving oxygen or mechanical ventilation, but not among those receiving no respiratory support.[12]
### Phases of drug trials
New medicines pass through numbered phases of clinical research. The U.S. Food and Drug Administration (FDA) describes them as follows (page current as of January 2018): phase 1 studies involve [20 to 100 healthy volunteers or people with the condition](https://www.fda.gov/patients/drug-development-process/step-3-clinical-research) and examine safety and dosage; phase 2 studies involve up to several hundred people with the condition and examine efficacy and side effects; phase 3 studies involve 300 to 3,000 people and examine efficacy and adverse reactions over one to four years; and phase 4 studies involve several thousand people and examine safety and efficacy. The FDA estimates that about 70 percent of drugs move from phase 1 to phase 2, about 33 percent from phase 2 to phase 3, and 25 to 30 percent from phase 3 onward.
New medicines pass through numbered phases of clinical research. The U.S. Food and Drug Administration (FDA) describes them as follows (page current as of January 2018): phase 1 studies involve [20 to 100 healthy volunteers or people with the condition](https://www.fda.gov/patients/drug-development-process/step-3-clinical-research) and examine safety and dosage; phase 2 studies involve up to several hundred people with the condition and examine efficacy and side effects; phase 3 studies involve 300 to 3,000 people and examine efficacy and adverse reactions over one to four years; and phase 4 studies involve several thousand people and examine safety and efficacy.[13] The FDA estimates that about 70 percent of drugs move from phase 1 to phase 2, about 33 percent from phase 2 to phase 3, and 25 to 30 percent from phase 3 onward.[13]
## Registration and reporting
## Registration and reporting
A trial whose results are published only when they are favourable gives a distorted picture of the evidence. In September 2004 the International Committee of Medical Journal Editors (ICMJE) stated that selective reporting [does occur, and it distorts the body of evidence available for clinical decision-making](https://pmc.ncbi.nlm.nih.gov/articles/PMC516198), and announced that its member journals would consider a trial only if it had been entered in a public registry before enrolment began: for trials starting enrolment after 1 July 2005, at or before that point, and for trials already under way, by 13 September 2005. At the time it named ClinicalTrials.gov, run by the U.S. National Library of Medicine, as the only registry known to meet its criteria. The World Medical Association's Declaration of Helsinki, in its October 2024 revision, likewise requires research involving human participants to be [registered in a publicly accessible database before recruitment of the first participant](https://www.wma.net/policies-post/wma-declaration-of-helsinki/), and states that negative and inconclusive as well as positive results must be made public.
A trial whose results are published only when they are favourable gives a distorted picture of the evidence. In September 2004 the International Committee of Medical Journal Editors (ICMJE) stated that selective reporting [does occur, and it distorts the body of evidence available for clinical decision-making](https://pmc.ncbi.nlm.nih.gov/articles/PMC516198), and announced that its member journals would consider a trial only if it had been entered in a public registry before enrolment began: for trials starting enrolment after 1 July 2005, at or before that point, and for trials already under way, by 13 September 2005.[10] At the time it named ClinicalTrials.gov, run by the U.S. National Library of Medicine, as the only registry known to meet its criteria.[10] The World Medical Association's Declaration of Helsinki, in its October 2024 revision, likewise requires research involving human participants to be [registered in a publicly accessible database before recruitment of the first participant](https://www.wma.net/policies-post/wma-declaration-of-helsinki/), and states that negative and inconclusive as well as positive results must be made public.[11]


*Via Wikimedia Commons: [TwiNS CONSORT Flow Diagram of identical twins diet trial](https://commons.wikimedia.org/wiki/File:TwiNS_CONSORT_Flow_Diagram_of_identical_twins_diet_trial.png) by Authors of the study: Matthew J. Landry, PhD, RDN1,2; Cather, [CC BY 4.0](https://creativecommons.org/licenses/by/4.0).*
*Via Wikimedia Commons: [TwiNS CONSORT Flow Diagram of identical twins diet trial](https://commons.wikimedia.org/wiki/File:TwiNS_CONSORT_Flow_Diagram_of_identical_twins_diet_trial.png) by Authors of the study: Matthew J. Landry, PhD, RDN1,2; Cather, [CC BY 4.0](https://creativecommons.org/licenses/by/4.0).*
How trials are written up is guided by the CONSORT statement (Consolidated Standards of Reporting Trials), [first published in 1996 and revised in 2001, 2010 and 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996237/). The 2025 version, by Sally Hopewell and colleagues, published on 14 April 2025 in several journals at once, is a 30-item checklist with a diagram tracking participants through each stage of the trial. It added an open science section covering trial registration, access to the protocol and statistical analysis plan, sharing of de-identified participant data and code, and authors' conflicts of interest, along with new items on how harms were assessed and how patients or the public were involved.
How trials are written up is guided by the CONSORT statement (Consolidated Standards of Reporting Trials), [first published in 1996 and revised in 2001, 2010 and 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996237/). The 2025 version, by Sally Hopewell and colleagues, published on 14 April 2025 in several journals at once, is a 30-item checklist with a diagram tracking participants through each stage of the trial. It added an open science section covering trial registration, access to the protocol and statistical analysis plan, sharing of de-identified participant data and code, and authors' conflicts of interest, along with new items on how harms were assessed and how patients or the public were involved.[9]
## Ethics
## Ethics
Leaving a control group without an effective treatment raises ethical questions. The Declaration of Helsinki allows a placebo or no intervention as the comparison [if no proven intervention exists](https://www.wma.net/policies-post/wma-declaration-of-helsinki/), or where it is methodologically necessary and participants will not be exposed to additional risk of serious or irreversible harm from not receiving the best proven intervention. In the 1948 streptomycin trial, the scarcity of the drug was part of the case for a comparison group.
Leaving a control group without an effective treatment raises ethical questions. The Declaration of Helsinki allows a placebo or no intervention as the comparison [if no proven intervention exists](https://www.wma.net/policies-post/wma-declaration-of-helsinki/), or where it is methodologically necessary and participants will not be exposed to additional risk of serious or irreversible harm from not receiving the best proven intervention.[11] In the 1948 streptomycin trial, the scarcity of the drug was part of the case for a comparison group.[4]
## Limits and criticisms
## Limits and criticisms
RCTs are often described as the "gold standard" of evidence. Deaton and Cartwright, in a 2018 paper in *Social Science & Medicine*, argue that [the gold standard or "truth" view does harm](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115) when it leads people to set aside other evidence, and they contest the idea that an average effect calculated from an RCT is automatically reliable. Their main points are that:
RCTs are often described as the "gold standard" of evidence. Deaton and Cartwright, in a 2018 paper in *Social Science & Medicine*, argue that [the gold standard or "truth" view does harm](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115) when it leads people to set aside other evidence, and they contest the idea that an average effect calculated from an RCT is automatically reliable.[8] Their main points are that:
- randomization balances the groups only on average, so a single trial can still be unbalanced by chance;
- a trial's estimate is the truth in the trial sample only, which is often [no more than a convenience sample](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115), so applying the result to other people or places requires further argument, a question usually called *external validity*;
- RCTs are most useful as part of a cumulative programme of research, combined with other methods, to learn not only "what works" but "why things work."
- randomization balances the groups only on average, so a single trial can still be unbalanced by chance;[8]
- a trial's estimate is the truth in the trial sample only, which is often [no more than a convenience sample](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115), so applying the result to other people or places requires further argument, a question usually called *external validity*;[8]
- RCTs are most useful as part of a cumulative programme of research, combined with other methods, to learn not only "what works" but "why things work."[8]
They add that they are [not against RCTs, only magical thinking about them](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115). The Cochrane bias domains show that a randomized trial can still go wrong after allocation, through missing data, unblinded outcome measurement or selective reporting of results.
They add that they are [not against RCTs, only magical thinking about them](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115).[8] The Cochrane bias domains show that a randomized trial can still go wrong after allocation, through missing data, unblinded outcome measurement or selective reporting of results.[6]
3 unchanged paragraphs
This entry explains; it is not medical advice. Ask a doctor or pharmacist about your own health.
This entry explains; it is not medical advice. Ask a doctor or pharmacist about your own health.
## Sources
## Sources
- Robert A. J. Matthews, "The problematic history of randomised controlled trials Part 1: presumption and confusion on the road to randomisation", *JLL Bulletin: Commentaries on the history of treatment evaluation*, James Lind Library, 2025. https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/
- James Lind, *A Treatise of the Scurvy, in Three Parts*, third edition (London, 1772), Part II, Chapter IV, digitized by the Internet Archive from the Wellcome Library. https://archive.org/details/b30511902
- James Lind Library, "Lind J (1753). A treatise of the scurvy". https://www.jameslindlibrary.org/lind-j-1753/
- John Crofton, "The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line", *Journal of the Royal Society of Medicine* 99, no. 10 (October 2006): 531–534. https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/
- Medical Research Council, "Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation", *British Medical Journal* 2, no. 4582 (30 October 1948): 769–782. https://pmc.ncbi.nlm.nih.gov/articles/PMC2091872/
- Julian P. T. Higgins, Jelena Savović, Matthew J. Page, Roy G. Elbers and Jonathan A. C. Sterne, "Chapter 8: Assessing risk of bias in a randomized trial", *Cochrane Handbook for Systematic Reviews of Interventions*, version 6.5 (Cochrane, 2024). https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08
- Julian P. T. Higgins, Sandra Eldridge and Tianjing Li, "Chapter 23: Including variants on randomized trials", *Cochrane Handbook for Systematic Reviews of Interventions*, version 6.5 (Cochrane, 2024). https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23
- Angus Deaton and Nancy Cartwright, "Understanding and misunderstanding randomized controlled trials", *Social Science & Medicine* 210 (2018): 2–21, doi:10.1016/j.socscimed.2017.12.005. https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115
- Sally Hopewell, An-Wen Chan, Gary S. Collins and others, "CONSORT 2025 statement: updated guideline for reporting randomised trials", *PLoS Medicine* 22, no. 4 (14 April 2025): e1004587. https://pmc.ncbi.nlm.nih.gov/articles/PMC11996237/
- International Committee of Medical Journal Editors, "Clinical trial registration: a statement from the International Committee of Medical Journal Editors", *CMAJ* 171, no. 6 (14 September 2004): 606–607. https://pmc.ncbi.nlm.nih.gov/articles/PMC516198
- World Medical Association, "Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants", adopted by the 75th WMA General Assembly, Helsinki, October 2024. https://www.wma.net/policies-post/wma-declaration-of-helsinki/
- RECOVERY Collaborative Group, "Dexamethasone in Hospitalized Patients with Covid-19", *New England Journal of Medicine*, published online 17 July 2020, doi:10.1056/NEJMoa2021436. https://pmc.ncbi.nlm.nih.gov/articles/PMC7383595/
- U.S. Food and Drug Administration, "Step 3: Clinical Research", content current as of 4 January 2018. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- Robert A. J. Matthews, "The problematic history of randomised controlled trials Part 1: presumption and confusion on the road to randomisation", *JLL Bulletin: Commentaries on the history of treatment evaluation*, James Lind Library, 2025. https://www.jameslindlibrary.org/articles/the-problematic-history-of-randomised-controlled-trials-part-1-presumption-and-confusion-on-the-road-to-randomisation/
- James Lind, *A Treatise of the Scurvy, in Three Parts*, third edition (London, 1772), Part II, Chapter IV, digitized by the Internet Archive from the Wellcome Library. https://archive.org/details/b30511902
- James Lind Library, "Lind J (1753). A treatise of the scurvy". https://www.jameslindlibrary.org/lind-j-1753/
- John Crofton, "The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line", *Journal of the Royal Society of Medicine* 99, no. 10 (October 2006): 531–534. https://pmc.ncbi.nlm.nih.gov/articles/PMC1592068/
- Medical Research Council, "Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation", *British Medical Journal* 2, no. 4582 (30 October 1948): 769–782. https://pmc.ncbi.nlm.nih.gov/articles/PMC2091872/
- Julian P. T. Higgins, Jelena Savović, Matthew J. Page, Roy G. Elbers and Jonathan A. C. Sterne, "Chapter 8: Assessing risk of bias in a randomized trial", *Cochrane Handbook for Systematic Reviews of Interventions*, version 6.5 (Cochrane, 2024). https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08
- Julian P. T. Higgins, Sandra Eldridge and Tianjing Li, "Chapter 23: Including variants on randomized trials", *Cochrane Handbook for Systematic Reviews of Interventions*, version 6.5 (Cochrane, 2024). https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23
- Angus Deaton and Nancy Cartwright, "Understanding and misunderstanding randomized controlled trials", *Social Science & Medicine* 210 (2018): 2–21, doi:10.1016/j.socscimed.2017.12.005. https://pmc.ncbi.nlm.nih.gov/articles/PMC6019115
- Sally Hopewell, An-Wen Chan, Gary S. Collins and others, "CONSORT 2025 statement: updated guideline for reporting randomised trials", *PLoS Medicine* 22, no. 4 (14 April 2025): e1004587. https://pmc.ncbi.nlm.nih.gov/articles/PMC11996237/
- International Committee of Medical Journal Editors, "Clinical trial registration: a statement from the International Committee of Medical Journal Editors", *CMAJ* 171, no. 6 (14 September 2004): 606–607. https://pmc.ncbi.nlm.nih.gov/articles/PMC516198
- World Medical Association, "Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants", adopted by the 75th WMA General Assembly, Helsinki, October 2024. https://www.wma.net/policies-post/wma-declaration-of-helsinki/
- RECOVERY Collaborative Group, "Dexamethasone in Hospitalized Patients with Covid-19", *New England Journal of Medicine*, published online 17 July 2020, doi:10.1056/NEJMoa2021436. https://pmc.ncbi.nlm.nih.gov/articles/PMC7383595/
- U.S. Food and Drug Administration, "Step 3: Clinical Research", content current as of 4 January 2018. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research